Based on our previous studies showing that HDAC and DNMT inhibitors produce better efficacy against lung cancer when used together [52], a combination of LBH589 and 5-Azacytidine (5-Aza) was used (Table S4). Here, DNMT1 is linked to lung carcinoma.